Polygenic Risk Tool Can Detect Clinically Significant Prostate Cancers

Polygenic Risk Tool Can Detect Clinically Significant Prostate Cancers

(MedPage Today) -- For men at the highest risk of prostate cancer as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been identified with the use of...

Test predicts which patients with prostate cancer most likely to develop long-term side effects from radiation therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.

expert reaction to the BARCODE1 trial assessing the use of a polygenic risk score in screening for prostate cancer

The results of the BARCODE1 trial, published by The New England Journal of Medicine assesses the use of a polygenic risk score in screening for prostate cancer.   Prof Michael Inouye, Professor of Systems Genomics & Population Health, University of Cambridge, said: “This study is the strongest evidence to date on the clinical utility of a polygenic score for prostate cancer screening. It shows that a polygenic score can improve early detection o…

Photothermal Treatment of Prostate Tumor with Micellar Indocyanine Green and Napabucasin to Co-Ablate Cancer Cells and Cancer Stem Cells

Scientists presented micellar indocyanine green and napabucasin that co-ablated cancer cells and cancer stem cells via photothermal therapy for the treatment of prostate tumors. [Journal of Controlled Release] AbstractGraphical Abstract

Dr Yu on Factors for PARP Inhibitor Decision-Making in Metastatic Prostate Cancer

Evan Ya-Wen Yu, MD, discusses considerations surrounding the tolerability of PARP inhibitors and how their adverse effect profiles influence treatment decisions in metastatic prostate cancer.

Pobel Translates PEACE-1 Trial Results Into Clinical Practice for mCSPC

Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.